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1. Introduction
There is a worldwide increase in antibiotic resistance, largely
related to inappropriate use of antibiotics; studies suggest that
inappropriate use of antibiotics for upper respiratory tract
infections (URTIs) adds to the burden.1
Viral infections cause the majority of URTIs. All clinicians
should know the natural history of the ‘common cold’ so that a
deviation from normal is managed effectively. Most important is
an appreciation that clear nasal secretions frequently become
purulent without signifying secondary bacterial disease, and that
coughing is a normal accompaniment (Fig. 1).
The organisms responsible for most bacterial URTIs are similar
in all age groups. Streptococcus pneumoniae is by far the
commonest organism causing otitis media and sinusitis. 
S. pyogenes is the only significant bacterial cause of pharyngitis.
Systematic reviews suggest that in developed countries the
benefit of antibiotics for pharyngitis and otitis media is extremely
limited; however, there are few data from poorer countries where
rheumatic fever and suppurative complications such as
mastoiditis are likely to be more common.2,3
South African experience suggests a high prevalence of
rheumatic fever, despite poor notification rates. For example, 66
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Introduction. Inappropriate use of antibiotics for upper
respiratory tract infections (URTIs), many of which are viral,
adds to the burden of antibiotic resistance. Antibiotic
resistance is increasing in Streptococcus pneumoniae,
responsible for most cases of acute otitis media (AOM) and
acute bacterial sinusitis (ABS).
Method. The Infectious Diseases Society of Southern Africa
held a multidisciplinary meeting to draw up a national
guideline for the management of URTIs. Background
information reviewed included randomised controlled trials,
existing URTI guidelines and local antibiotic susceptibility
patterns. The initial document was drafted at the meeting.
Subsequent drafts were circulated to members of the working
group for modification. The guideline is a consensus
document based upon the opinions of the working group.
Output. Penicillin remains the drug of choice for
tonsillopharyngitis. Single-dose parenteral administration of
benzathine penicillin is effective, but many favour oral
administration twice daily for 10 days. Amoxycillin remains
the drug of choice for both AOM and ABS. A dose of 90 mg/
kg/day is recommended in general, which should be effective
for pneumococci with high-level penicillin resistance (this is
particularly likely in children ≤ 2 years of age, in day-care
attendees, in cases with prior AOM within the past 6 months,
and in children who have received antibiotics within the last
3 months). 
Alternative antibiotic choices are given in the guideline
with recommendations for their specific indications. These
antibiotics include amoxycillin-clavulanate, some
cephalosporins, the macrolide/azalide and ketolide groups of
agents and the respiratory fluoroquinolones. 
Conclusion. The guideline should assist rational antibiotic
prescribing for URTIs. However, it should be updated when
new information becomes available from randomised
controlled trials and surveillance studies of local antibiotic
susceptibility patterns. 
Nasal stuffiness
&
throat irritation
Mucopurulent
secretions
(1 - 3 d later)
Persists up to 10 days
in 35%
Low-grade fever, malaise,
myalgia, anorexia
Sneezing
&
watery nasal discharge
Cough in 60 - 80%
(does not imply 
bacterial disease)
Persists up to 10 days 
in 31%
Fig. 1. Natural history of the common cold.
Please forward all comments to: Dr A J Brink, tel. (011) 726-6260, e-mail
brinka@ampath.co.za 
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new cases of rheumatic heart disease are referred annually to the
paediatric cardiology clinic at the Johannesburg General Hospital
(personal communication — Dr W Hendson). In the Western
Cape, 49 new cases are seen every year at Red Cross War
Memorial and Tygerberg Children’s hospitals (personal
communication — Dr J Lawrenson and Professor P L van der
Merwe). At Umtata General Hospital, 125 children with
rheumatic fever were admitted between January 1998 and
January 2000, comprising 2% of paediatric admissions. The
majority (76%) had two or more episodes of rheumatic fever,
which was strongly associated with overcrowding (> 6 people
per room) (personal communication — Professors A S Savio and
A Targonski, University of Transkei). 
By establishing simple guidelines recommending antibiotics
with a relatively narrow spectrum, patients ought to be well
managed and serious complications avoided. The most
frequently recommended first-line antibiotics remain penicillin
and amoxycillin. 
The recommendations for duration of therapy differ;
pharyngotonsillitis and acute bacterial sinusitis (ABS) should be
treated for 5 - 10 days and acute otitis media (AOM) for 5 - 7
days. In this regard, recent evidence suggests that a shorter
duration of antibiotic treatment is associated with less emergence
of resistant pathogens.4
The recommendations for frequency of administration vary
according to the site of infection and the pharmacokinetic/
pharmacodynamic (PK/PD) profiles of the drugs used; in AOM a
twice-daily dose of amoxycillin has the same clinical efficacy as 3
times a day. 
For optimal clinical success, the antibiotic dosage must be
tailored to the individual. The most common cause of treatment
failure and antibiotic resistance is sub-optimal dosing. For
example in AOM, 5 ml is erroneously prescribed as a standard
dose for a child weighing 5 - 15 kg instead of individualising
doses by body mass. Dosages given in this guideline include both
the registered standard doses and higher doses, which are
recommended for use in situations where high-level antibiotic
resistance has been reported. Except for amoxycillin and
amoxycillin-clavulanate, all paediatric doses are given as mg per
kg per dose followed by frequency of daily administration. 
Recommendations have been made based on national
surveillance of appropriate pathogens and relevant publications.5
For S. pneumoniae, the most common pathogen causing otitis
media and acute sinusitis, resistance to β-lactam antibiotics can
be overcome by increasing dosage. For example, a higher dose of
amoxycillin of 90 mg/kg/day is generally recommended for
treatment of AOM. Because of concerns about the existence of
macrolide resistance among isolates of S. pneumoniae in some
areas of practice in South Africa, in those circumstances this class
should preferably be reserved for patients with β-lactam
antibiotic allergy. 
The guideline gives indications for recommended first-line
agents as well as alternative choices of antibiotics. The first-line
antibiotics are the agents of choice and remain penicillin or
amoxycillin. The indications for alternative antibiotics may
include the following:
• Allergy or intolerance to first-line agents.
• Recent prior use of first-line agents.
• High-risk cases likely or known to be infected with highly
resistant organisms. Consideration needs to be given to 
β-lactam and macrolide resistance.
• Failed initial therapy.
Few guidelines have been subjected to the rigours of
prospective evaluation and most are based on best practice,
taking into account unique local circumstances. In South Africa,
widespread implementation of throat cultures for pharyngitis is
unlikely to occur because an extensive infrastructure would need
to be established for an easily treated condition.
2. Acute pharyngotonsillitis
Pharyngotonsillitis is an inflammatory condition of the
pharyngeal wall, sometimes divided into pharyngitis and
tonsillitis. Respiratory viruses are the major cause of pharyngitis
and include the Epstein-Barr virus that causes infectious
mononucleosis. Bacteria, especially group A β-haemolytic
streptococci (GABHS) (S. pyogenes), account for between 5% and
30% of cases. In terms of the ability of throat cultures to diagnose
streptococcal pharyngotonsillitis, the specificity approaches 80%
while the sensitivity is only 30%, when compared with a rise in
or a high level of antistreptolysin O titre.6 Non-infectious causes
of pharyngitis include allergy and exposure to irritating
substances. 
Although in most instances GABHS tonsillitis is usually self-
limited, antibiotics are recommended to prevent the suppurative
and non-suppurative (acute rheumatic fever, glomerulonephritis)
post-streptococcal sequelae. The only known risk factor for
rheumatic fever is pharyngitis caused by rheumatogenic strains
of GABHS, common in both poor rural and urban environments
in South Africa. The recommendations of the guideline should
therefore be easy to apply and should be such that they would be
associated with prevention of rheumatic fever.
2.1 Treatment of streptococcal pharyngotonsillitis 
The treatment of choice is penicillin.
2.1.1 Penicillin
There is evidence that intramuscular penicillin prevents
rheumatic fever.7 Although intramuscular injections are not
popular, attempts should be made to administer penicillin
parenterally if compliance and follow-up are unlikely. The
mixture of benzathine penicillin and procaine penicillin results in
a less painful injection.8 Penicillin can be given twice or 3 times
daily by mouth instead of 4 times a day, as previously
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recommended.  Penicillin should be given 30 minutes before a
meal as food may reduce its absorption. A 10-day course is still
recommended. An important point for continued use of penicillin
is the lack of resistance by GABHS, as opposed to erythromycin
and other macrolides, where resistance is associated with
excessive use.9,10 Furthermore, a particular advantage of penicillin
is its narrow spectrum of activity.
Children
• Penicillin VK 
250 mg twice daily for 10 days (≤ 27 kg)
500 mg twice daily for 10 days (> 27 kg) 
(given 30 minutes before food). 
• Benzathine penicillin (intramuscular injection)*
3 - 5 yrs:  600 000 U 
> 5 yrs: 1.2 MU.
Adults and adolescents
• Penicillin VK, 500 mg twice daily for 10 days (given 30 minutes
before food)
• Benzathine penicillin (intramuscular injection), 1.2 MU as
single dose.*
2.1.2 Amoxycillin
Amoxycillin is an alternative to penicillin VK and has the
advantage of no food restrictions. However, a rash can occur
where pharyngotonsillitis is due to Epstein-Barr virus infection.
This can lead to an erroneous diagnosis of penicillin allergy or,
rarely, a severe skin reaction. Therefore amoxycillin should
preferably only be used when GABHS has been identified by
culture.
Children
• Amoxycillin, 25 mg/kg twice daily for 10 days.
Adults
• Amoxycillin, 500 mg twice daily for 10 days.
2.1.3 Short-course therapy (3 - 5 days)
Short-course therapy is a recent development.12-17 Adam and
colleagues12 showed equivalence between penicillin given 3
times daily for 10 days and a number of regimens (including
use of new macrolides or second-generation cephalosporins)
given for 5 days.12
The list of agents that have been used for short-course
therapy is given below.
Children 
• Amoxycillin-clavulanate, 40 mg/kg/day in 3 divided doses 
• Azithromycin, 10 - 20 mg/kg once daily for 3 days 
• Clarithromycin, 7.5 mg/kg twice daily 
• Cefpodoxime, 4 mg/kg twice daily
• Cefprozil, 7.5 mg/kg twice daily  
• Cefuroxime, 10 mg/kg twice daily. 
Adults
• Amoxycillin-clavulanate, 375 mg 3 times daily  
• Azithromycin, 500 mg once daily for 3 days
• Clarithromycin (modified release), 500 mg once daily 
• Cefpodoxime, 100 mg twice daily
• Cefprozil, 500 mg twice daily
• Cefuroxime, 250 mg twice daily  
• Telithromycin, 800 mg once daily.  
3. Acute otitis media
AOM is one of the most common childhood illnesses — an
estimated 75% of children have had more than 1 episode by 3
years of age. The prevalence is increasing in children less than
2 years of age, and in those attending day-care facilities or
exposed to passive smoking.18
The main bacterial causes of AOM are S. pneumoniae, non-
typable Haemophilus influenzae and Moraxella catarrhalis. While
there is a high rate  (~60 - 70%) of spontaneous resolution of
AOM caused by H. influenzae and M. catarrhalis, S. pneumoniae
infection is the least likely to resolve spontaneously and
therefore the most important target for antibiotic therapy.
Antibiotic resistance in S. pneumoniae is often clinically relevant
because of the relatively poor permeability of antibiotics into
the middle ear fluid (MEF). 
While most of the drugs approved for AOM have good in
vitro activity against the common AOM pathogens, there are
many differences in their in vivo activity and penetration into
the MEF. Studies in which efficacy of antibiotics used for AOM
is measured by symptomatic relief fail to discern major
differences between drugs because of the so-called ‘Pollyanna
phenomenon’: drugs with poor in vivo activity appear to be
effective because of the high rate (67%) of spontaneous
recovery of the infection.19
Given the high rate of spontaneous resolution of AOM, and
the probable viral aetiology, particularly in older infants, some
authorities argue that antibiotics should be deferred for at least
48 hours during which the patient is given analgesics and
decongestants.20 A useful approach may be to dispense the
antibiotic or provide a prescription, with the instruction that it
is to be given (or the prescription filled) if there has not been
resolution by 48 hours. This approach is reasonable where
good follow-up is possible in children ≥ 2 years of age. 
However, because of the risks of a serious infection with 
S. pneumoniae and possible limited access of some patients to
health care in South Africa, we recommend that all cases be
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*Note: To minimise the discomfort of parenteral administration, the medication should
be given at room temperature. For patients receiving 1.2 million U, 300 000 U can be
given as procaine penicillin.11
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treated from the first visit provided that the AOM is correctly
diagnosed and distinguished from otitis media with effusion
(glue ear); for this reason the eardrum must be visualised
during examination. Because pneumatoscopy is seldom used in
South Africa and crying can cause a red tympanum, AOM is
probably seldom correctly diagnosed. In a recent survey of
paediatricians attending a training session on otitis media
management from four countries including South Africa, only
half were able to make an accurate otoscopic diagnosis after
training.21 For otitis media associated with a bulging
tympanum and a temperature > 38°C, immediate treatment
should be considered. Another reason for immediate antibiotic
use is inability to predict whether the patient will have
spontaneous resolution. 
Antibiotics are essential if AOM is diagnosed in the
following patients: 
• Recurrent AOM
• Immunocompromised patients
• Neonates
• Structural ENT or immunological abnormalities
• Fever (temperature > 38°C) or pain > 48 hours
• Day-care attendees or siblings of children attending day-care
centres.
Risk factors for resistant S. pneumoniae infections include age
(≤ 2 years), attendance at day-care centres or siblings of
children attending day-care centres, prior AOM within the past
6 months, and receipt of antibiotics within the last 3 months.
These influence the choice and dosage of antibiotics. 
Paracetamol (10 - 15 mg/kg 4 - 6-hourly) or ibuprofen 
(10 mg/kg 8-hourly) should be given for analgesia (under- and
overdosing are common). Although decongestants are widely
prescribed for rhinitis, their use in AOM is controversial. If
used, topical application for a maximum of 3 days is preferable
to oral administration. 
Otitis media may be part of neonatal sepsis and any neonate
with fever should be evaluated for sepsis. Investigations
should include a blood culture, urine microscopy, culture and
sensitivity testing and lumbar puncture in cases where
hypothermia (temperature < 35°C) or pyrexia (temperature 
> 38°C) have been noted. Possible causative organisms in AOM
include coliforms, group B streptococci and Staphylococcus
aureus. Where neonatal sepsis has been excluded and oral
therapy is indicated for treatment of AOM, amoxycillin-
clavulanate should be given.22 In a recent Israeli study of
infants under 2 months of age in whom tympanocentesis had
been done, the spectrum of pathogens cultured was similar to
that in older children. S. pneumoniae was the most common
isolate (46%), of which 20% were not susceptible to penicillin.
For this reason, the use of a higher dose of amoxycillin 
(90 mg/kg/day) or amoxycillin-clavulanate, plus additional
amoxycillin (to a total dose of amoxycillin of 90 mg/kg/day),
would be appropriate.23
3.1 Treatment of AOM
The treatment of choice, except in neonates, is amoxycillin.
3.1.1 Amoxycillin
The dosage recommended is 90 mg/kg/day. This higher
dosage is generally recommended since it should provide
adequate cover for pneumococcal isolates with high-level
penicillin resistance, particularly prevalent in the following
circumstances:
• Age ≤ 2 years
• Day-care attendees or siblings of children attending day-care
centres 
• AOM in previous 6 months
• Receipt of antibiotics during the 3 months preceding the
AOM episode.
At the standard dosage of 40 - 50 mg/kg/day, amoxycillin is
likely to be reasonably effective for an initial episode of AOM
in cases infected with non-β-lactamase-producing H. influenzae
and penicillin-susceptible and possibly intermediate-resistant
S. pneumoniae. This dosage may not be high enough to
eradicate highly penicillin-resistant strains with minimum
inhibitory concentrations (MICs) ≥ 2 µg/ml. 
3.1.2 Amoxycillin-clavulanate
The addition of a β-lactamase inhibitor extends the spectrum of
amoxycillin against β-lactamase-producing H. influenzae and M.
catarrhalis. A higher dosage of amoxycillin-clavulanate 
(90 mg/kg/day of amoxycillin and a constant amount of
clavulanate 6.4 mg/kg/day) was recently evaluated in a
double-tap study (tympanocentesis at the beginning and end of
treatment course). All penicillin-susceptible and intermediate-
resistant and 91% of high-level penicillin-resistant pneumococci
were eradicated. In addition, 95% of H. influenzae and all M.
catarrhalis were eradicated.24 Until this formulation is
registered in South Africa, amoxycillin should be added to
amoxycillin-clavulanate to give 90 mg/kg/day of amoxycillin.  
3.1.3 Oral cephalosporins
Cefuroxime axetil, cefprozil and cefpodoxime are the only oral
cephalosporins that may reach MEF levels sufficiently above
the MIC for both penicillin-sensitive and some intermediate-
resistant S. pneumoniae and for H. influenzae.25 Considering the
high prevalence of β-lactam resistance in many areas of South
Africa, it is recommended that if these cephalosporins are used
for treatment of AOM, they should be prescribed at the higher
dosages detailed below. The bacterial efficacy of cefpodoxime
has not been evaluated in prospective, comparative, double-tap
studies.  Cefaclor, cefixime and loracarbef are less active in vitro
against S. pneumoniae and are not recommended.
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3.1.4 Parenteral cephalosporins
The MEF concentration of ceftriaxone exceeds the MICs for
AOM pathogens for > 50 hours after a single 50 mg/kg
intramuscular injection. However, a 3-day regimen is clinically
superior, particularly in non-responsive AOM caused by
penicillin-resistant S. pneumoniae.26 Ceftriaxone use should be
restricted to cases with failure of high-dose amoxycillin-
clavulanate or for severe presentations. 
3.1.5 Macrolides/azalide/clindamycin
Erythromycin should not be used for the empiric treatment of
AOM owing to substantial resistance of S. pneumoniae and H.
influenzae and sub-optimal PK/PD parameters. Azithromycin
and clarithromycin have good in vitro activity against
macrolide-susceptible pneumococci and M. catarrhalis and
acceptable activity against H. influenzae. However, double-tap
studies have recently demonstrated that azithromycin at
standard doses failed to eradicate macrolide-resistant
pneumococci and H. influenzae.27 In areas with a high
prevalence of macrolide resistance macrolides should therefore
preferably be restricted to cases with β-lactam allergy, or used
for suspected or proven infections with ‘atypical’ pathogens.
Clindamycin retains activity against most penicillin-resistant
S. pneumoniae but has no activity against H. influenzae or 
M. catarrhalis. It can be used in confirmed, clindamycin-
susceptible, pneumococcal AOM, unresponsive to β-lactam
antibiotics.
3.1.6 Trimethoprim-sulfamethoxazole (TMP-SMX)
The high rate of resistance of S. pneumoniae in South Africa
precludes the use of TMP-SMX. High bacteriological failure
rates have been noted to occur in double-tap studies.28
3.2 Duration of therapy for AOM
Most antibiotics are clinically effective for uncomplicated AOM
when used in regimens of 5 - 7 days, since eradication of
organisms takes place within 72 hours.29 However, therapy
beyond 72 hours is required for adequate eradication of
potentially pathogenic bacteria colonising the nasopharynx,
because if these are not successfully eradicated they may
predispose to relapses of AOM. 
Further studies are needed to determine optimal duration of
therapy in children younger than 2 years of age and in patients
with non-responsive AOM.25,30 Until then, therapy for 7 - 10
days is recommended for AOM in the following groups:
• Age ≤ 2 years  
• Recurrent or chronic AOM
• Complicated AOM.
3.3 Failure to respond to antibiotics
In cases of clinical failure (e.g. persistent fever) after 72 hours
of appropriate, compliant initial antibiotic therapy, consider
referral to an otorhinolaryngologist for tympanocentesis and
MEF culture. This is of relevance in areas with a high
prevalence of antibiotic-resistant S. pneumoniae, as is the case
for the majority of major urban centres in South Africa,
particularly in the private sector.
3.4 Antibiotic recommendations for AOM
3.4.1 Children
First-line recommended therapy:
• Amoxycillin, 90 mg/kg/day into 2 or 3 divided doses for 5 -
7 days.
Alternative antibiotic choices:
(a) Beta-lactamase-stable antibiotics:
• Amoxycillin-clavulanate, plus additional amoxycillin (to a
total dose of amoxycillin of 90 mg/kg/day) divided into 2 or
3 doses for 5 - 7 days
• Cefpodoxime proxetil, 8 - 16 mg/kg twice daily for 5 - 7 days 
• Cefprozil, 15 - 30 mg/kg twice daily for 5 - 7 days
• Cefuroxime axetil, 15 - 30 mg/kg twice daily for 5 - 7 days.
The higher dosages of cephalosporins recommended would
cover for most pneumococcal isolates of intermediate resistance
to penicillin, but not necessarily for pneumococcal isolates with
high-level resistance. The particular choice of cephalosporins
would depend on physician or patient preference, availability
and cost. Risk factors for AOM caused by β-lactamase-
producing pathogens may include immunocompromised
patients and/or neonates.
(b) Antibiotics for β-lactam allergy:
• Azithromycin, 10 mg/kg once daily for 3 days* 
• Clarithromycin, 7.5 - 15 mg/kg twice daily for 5-7 days* 
• Erythromycin estolate, 40 mg/kg twice daily for 5 - 7 days* 
• Cefpodoxime proxetil, 8 - 16 mg/kg twice daily for 5 - 7
days†
• Cefprozil, 15 - 30 mg/kg twice daily for 5 - 7 days†
• Cefuroxime axetil, 15 - 30 mg/kg twice daily for 5-7 days†.
(c) Failed initial therapy:
• Amoxycillin-clavulanate, plus additional amoxycillin (to a
total dose of amoxycillin of 90 mg/kg/day) divided into 2 or
3 doses for 5 - 7 days for failed initial therapy with
amoxycillin alone 
• Ceftriaxone, intravenous (IV) or intramuscular (IM), 50 - 75
mg/kg once daily for 3 days. This is also recommended in
the case of isolates of known high-level antibiotic resistance
and in severe presentations, e.g. threatened mastoiditis,
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*Macrolides/azalide are recommended for patients who have severe β-lactam allergy. 
†Cephalosporins may be considered initially for patients with penicillin intolerance/non-
type 1-hypersensitivity reactions (e.g. rash).
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preferably in consultation with an otorhinolaryngologist. 
3.4.2 Adults
The treatment options for AOM in adults are the same as for
acute bacterial sinusitis.
4. Acute bacterial sinusitis
ABS is most often preceded by a viral URTI. Allergy, trauma,
dental infection, or other factors that lead to inflammation of
the nose and paranasal sinuses may also predispose
individuals to ABS.
The most common bacterial isolates from the maxillary
sinuses of patients with ABS are similar to those isolated in
AOM, namely S. pneumoniae, H. influenzae and M. catarrhalis.
As with AOM, S. pneumoniae causes most of the serious
sequelae and antibiotic therapy must be capable of eradicating
it. Other streptococcal species, anaerobic bacteria and S. aureus
occur in a small percentage of cases. Chlamydia pneumoniae and
other ‘atypical’ pathogens should be considered in patients
with chronic sinusitis.31 Fungi have been associated with
sinusitis and may be seen in allergic sinusitis and
immunocompromised hosts. However, their clinical
significance in immunocompetent patients is unclear.
Multiple factors play a role in the antibiotic selection for
ABS. S. pneumoniae may be associated with serious intracranial
and extrasinus complications, so it should be adequately
covered in initial therapy. Gram-negative cover for H. influenzae
(and M. catarrhalis in children) cannot be ignored. 
Prior antibiotic use is a major risk factor for infection with
antibiotic-resistant strains. Because recent antibiotic exposure
increases the risk of carriage and infection with resistant
organisms, the choice and dosage of antimicrobial therapy
should take into account a history of recent antibiotic use.
Other factors to consider are the severity of disease, its rate of
progression and varying rates of resistance within South Africa. 
4.1 Duration of antibiotic treatment for ABS
The duration of antibiotic treatment for ABS is 10 days. This is
based on published studies of clinical trials in which pre-
treatment and post-treatment sinus aspirates were performed.32
However, recent evidence for gatifloxacin, moxifloxacin and
telithromycin suggests that a shorter course of 5 - 7 days is
clinically and/or bacteriologically equivalent to a 10-day
course.33-35
4.2 Failure to respond to antibiotics
In cases of clinical failure (e.g. persistent fever) after 72 hours
of appropriate, compliant antibiotic therapy, consider referral
to an otorhinolaryngologist for further evaluation. A computed
tomography (CT) scan, fibre-optic endoscopy, or sinus
aspiration and culture may be necessary. This is of relevance 
in areas with a high prevalence of antibiotic-resistant 
S. pneumoniae, as is the case for the majority of major urban
centers in South Africa, particularly in the private sector. 
4.3 Beta-lactam allergy
Clinicians should differentiate an immediate type-1 hypersensi-
tivity reaction from other less dangerous side- effects. Urticaria,
angio-oedema and bronchospasm are especially dangerous
signs and should contraindicate use of antibiotics that have
caused these reactions in a patient in the past.  Patients with
other types of reactions and side-effects may tolerate one
specific β-lactam but not another. The cross-reactivity for
penicillin and first-generation cephalosporins is higher than for
second- or third-generation cephalosporins. Consensus opinion
suggests that if the previous reaction to penicillin was an itchy
maculopapular rash, it would be relatively safe to use
cephalosporins.36 This approach may be followed if the allergy
to penicillin was mild, the indication for cephalosporins is well
motivated and skin testing for penicillin is impractical.
4.4 Antibiotic recommendations for ABS
4.4.1 Children
First-line recommended therapy:
• Amoxycillin, 90 mg/kg/day into 3 divided doses for 10
days.
Alternative antibiotic choices:
(a) Beta-lactamase-stable antibiotics:
• Amoxycillin-clavulanate, plus additional amoxycillin (to a
total dose of amoxycillin of 90 mg/kg/day) divided into 3
doses for 10 days
• Cefpodoxime proxetil, 8 - 16 mg/kg twice daily for 10 days 
• Cefprozil, 15 - 30 mg/kg twice daily for 10 days
• Cefuroxime axetil, 15 - 30 mg/kg twice daily for 10 days.
The higher dosages of cephalosporins recommended would
cover for most pneumococcal isolates of intermediate resistance
to penicillin but not necessarily for pneumococcal isolates with
high-level resistance. The particular choice of cephalosporins
would depend on physician or patient preference, availability
and cost. Risk factors for ABS caused by β-lactamase-producing
pathogens may include immunocompromised patients and/or
neonates.
(b) Antibiotics for β-lactam allergy:
• Azithromycin, 10 mg/kg once daily for 3 days* 
• Clarithromycin, 7.5 - 15 mg/kg twice daily for 10 days* 
• Erythromycin estolate, 40 mg/kg twice daily for 10 days* 
*Macrolides/azalide are recommended for severe β-lactam allergy in children.
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• Cefpodoxime proxetil, 8 - 16 mg/kg twice daily for 10 days*
• Cefprozil, 15 - 30 mg/kg twice daily for 10 days*
• Cefuroxime axetil, 15 - 30 mg/kg twice daily for 10 days*.
(c) Failed initial therapy: 
• Amoxycillin-clavulanate, plus additional amoxycillin (to a
total dose of amoxycillin of 90 mg/kg/day) divided into 3
doses for 10 days for failed initial therapy with amoxycillin
alone 
• Ceftriaxone, IV or IM, 50 - 75 mg/kg once daily for 
3 - 5 days. This is also recommended in the case of isolates of
known high-level antibiotic resistance and in severe
presentations, e.g. peri-orbital inflammation, preferably in
consultation with an otorhinolaryngologist.
4.4.2 Adults
First-line recommended therapy:
• Amoxycillin, 1 g 3 times daily for 10 days.
Alternative antibiotic choices:
(a) Beta-lactamase-stable antibiotics:
• Amoxycillin-clavulanate, 1 g twice daily plus amoxycillin
500 mg twice daily for 10 days  
• Cefpodoxime proxetil, 200 - 400 mg twice daily for 10 days 
• Cefprozil, 500 mg - 1 g twice daily for 10 days
• Cefuroxime axetil, 500 mg - 1 g twice daily for 10 days.
The higher dosages of cephalosporins recommended would
cover for most pneumococcal isolates of intermediate resistance
to penicillin but not necessarily for pneumococcal isolates with
high-level resistance. The particular choice of cephalosporins
would depend on physician or patient preference, availability
and cost. Risk factors for ABS caused by β-lactamase-producing
pathogens may include immunocompromised patients,
including pregnant patients and diabetics.
(b) Antibiotics for β-lactam allergy:
• Azithromycin, 500 mg once daily for 3 days†
• Clarithromycin (modified release), 1 000 mg once daily for 10
days†
• Erythromycin, 500 mg 4 times daily for 10 days†
• Telithromycin, 800 mg once daily for 5 - 10 days†
• Cefpodoxime proxetil, 200 - 400 mg twice daily for 10 days*
• Cefprozil, 500 mg - 1 g twice daily for 10 days*
• Cefuroxime axetil, 500 mg - 1 g twice daily for 10 days*
• Gatifloxacin, 400 mg once daily for 5 - 10 days‡
• Levofloxacin, 500 mg once or twice daily for 10 days‡
• Moxifloxacin, 400 mg once daily for 7 - 10 days‡
• Clindamycin, 450 mg three times daily for 10 days.§
(c) Failed initial therapy: 
• Amoxycillin-clavulanate, 1 g twice daily plus amoxycillin
500 mg twice daily for 10 days for failed initial therapy with
amoxycillin alone
• Respiratory fluoroquinolones:
• Gatifloxacin, 400 mg once daily for 5 - 10 days
• Levofloxacin, 500 mg once or twice daily for 10 days
• Moxifloxacin, 400 mg once daily for 7 - 10 days
• Telithromycin, 800 mg once daily for 5 - 10 days
• Ceftriaxone, IV or IM, 1 - 2 g once daily for 3 - 5 days.
Ceftriaxone or the respiratory fluoroquinolones may also be
used as first-line therapy in severe initial presentations, e.g.
peri-orbital oedema, preferably in consultation with an
otorhinolaryngologist.
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1. SORE THROAT
Clinical diagnosis of streptococcal pharyngotonsillitis
Points in favour of empiric antimicrobial treatment:
• Acute onset
• Temperature > 38°C
• Tender anterior cervical nodes
• Tonsillar erythema/exudates
• Age 3 - 15 years
• Previous rheumatic fever or rheumatic heart disease
Points against empiric antimicrobial treatment: 
• Rhinorrhoea
• Cough
• Diarrhoea
• Conjunctivitis
• Age > 45 years
Treatment of choice
The treatment of choice is penicillin:
Children:
• Penicillin VK 
250 mg twice daily for 10 days  (≤ 27 kg)
500 mg twice daily for 10 days (> 27 kg) 
• Benzathine penicillin (intramuscular injection)*
3 - 5 yrs:  600 000 U
> 5 yrs: 1.2 MU
Adults and adolescents:
• Penicillin VK, 500 mg twice daily for 10 days
• Benzathine penicillin (intramuscular injection)* 1.2 MU
For patients with severe β-lactam allergy:
Children:
• Erythromycin estolate, 40 mg/kg twice daily for 10 days
• Azithromycin, 10 - 20 mg/kg once daily for 3 days
• Clarithromycin, 7.5 - 15 mg/kg twice daily for 5 days
Adults:
• Erythromycin estolate, 500 mg twice daily for 10 days
• Azithromycin, 500 mg once daily for 3 days 
• Clarithromycin (modified release), 500 mg once daily for 5 days
• Telithromycin, 800 mg once daily for 5 days
Indications for referral
Local complications:
• Peritonsillar sepsis including quinsy abscess-cellulitis-trismus
(asymmetrical peritonsillar swelling)
• Recurrent infections (4 or more episodes/year)
• Non-response to initial therapy
Systemic complications:
• Acute rheumatic fever
• Severe systemic illness
Special investigations
Throat swabs should be reserved for patients with recurrent sore
throats
2. ACUTE OTITIS MEDIA (AOM)
Clinical diagnosis of AOM
• Visualisation of the eardrum is essential for diagnosis 
• Bulging, red or yellow tympanic membrane
• Ancillary features include:
• Otalgia 
• Temperature > 38°C
(Note: an effusion alone is not an indication for antimicrobials)
Treatment of choice
The treatment of choice is oral amoxycillin:
Children†:
• Amoxycillin, 90 mg/kg/day in 2 or 3 divided doses  
Adults:
• Amoxycillin, 1 000 mg 3 times daily for 5 days
*Note: To minimise the discomfort of parenteral administration, the medication should be
given at room temperature. For patients receiving 1.2 million U, 300 000 U can be given as
procaine penicillin.
†Duration of therapy: 5 - 7 days except ≤ 2 years of age and complicated cases (7  - 10 days).
For patients with severe β-lactam allergy:
Children:
• Erythromycin estolate, 40 mg/kg twice daily for 5 - 7 days
• Azithromycin, 10 mg/kg once daily for 3 days 
• Clarithromycin, 7.5 - 15 mg/kg twice daily for 5 - 7 days
Adults:
• Erythromycin estolate, 500 mg qid for 5 - 7 days
• Azithromycin, 500 mg once daily for 3 days 
• Clarithromycin (modified release), 500 mg or 1 g once daily for 
5 - 7 days
Indications for referral
• If tympanic membrane is not visualised
• Non-responsive AOM (no improvement after 3 days of treatment)
• Suspected intracranial extension
• Lower motor neuron VIIth nerve palsy
• Suspected mastoiditis
3. ACUTE BACTERIAL SINUSITIS (ABS)
Diagnosis of ABS
Consider in adults or children with an upper respiratory tract
infection that is NOT improving after 10 days or worsens after 5 - 7
days and is accompanied by some or all of these symptoms:
• Fever 
• Facial tenderness, particularly unilateral or focused in the region
of a sinus group (peri-orbital, maxillary, frontal or ethmoidal)
• Dental tenderness
• Nasal discharge, nasal congestion, anosmia (loss of sense of
smell), cough, ear fullness and pressure
(Frontal sinusitis does not occur in toddlers < 4 years because of
delayed development of the frontal sinuses)
Treatment of choice
The treatment of choice is oral amoxycillin:
Children:
• Amoxycillin, 90 mg/kg/day in 3 divided doses for 10 days
Adults:
• Amoxycillin, 1 g 3 times daily for 10 days
For patients with severe β-lactam allergy:
Children:
• Erythromycin estolate, 40 mg/kg twice daily for 10 days
• Azithromycin, 10 mg/kg once daily for 3 days 
• Clarithromycin, 15 mg/kg twice daily for 10 days 
Adults:
• Macrolides: 
• Erythromycin, 500 mg 4 times daily for 10 days
• Clarithromycin (modified release), 1 000 mg once daily for 10
days
• Azithromycin, 500 mg once daily for 3 days
• Telithromycin, 800 mg once daily for 5 - 10 days
• Fluoroquinolones:  
• Gatifloxacin, 400 mg once daily for 5 - 10 days
• Levofloxacin, 500 mg once or twice daily for 10 days
• Moxifloxacin, 400 mg once daily for 7 - 10 days
• Clindamycin, 450 mg 3 times daily for 10 days 
Criteria for referral
• Failure to respond after 72 hours
• Peri-orbital swelling
• Evidence of CNS extension (meningism, focal neurological signs,
altered level of consciousness)
• Severe systemic illness
• Chronic sinusitis – symptomatic > 30 days
Special investigations
• X-rays are of limited value  
• CT scans should be reserved for cases in which surgery is
considered
• Nasal swabs for microbiological investigation are of no value, and
specimens for culture and microscopy should only be collected
from sinus puncture
Summary: Antibiotic recommendations for upper respiratory tract infections
Notes
